Composition for improving skin inflammatory aging and application thereof

Abstract

The present application relates to the field of cosmetic technology, and in particular to a composition for improving skin inflammatory aging and its application. The composition comprises the following components: silybin phospholipid complex, phytol and silanediol salicylate; the silybin phospholipid complex comprises silybin and phospholipid. The present application combines the main functional ingredients silybin phospholipid complex, phytol and silanediol salicylate for compound use, and by optimizing the proportion of the components, the cosmetics can have better antioxidant, anti-inflammatory and anti-aging effects. Moreover, the three components complement each other in efficacy and have a synergistic effect.

Description

Technical Field

[0001] The present application relates to the technical field of cosmetics, and in particular to a composition for improving skin inflammatory aging and its application. Background Art

[0002] Inflammation is part of the body's defense mechanism and is triggered when the immune system recognizes and eliminates harmful internal or external stimuli and begins healing. Aging is a common, complex, and naturally occurring process.

[0003] Chronic inflammation is closely related to aging. After aging, cells will secrete pro-inflammatory factors, such as IL-1α, IL-6, IL-8, TNF-α and other cytokines, proteases and regulators such as MMP-1.

[0004] As we age, our immune system gradually degenerates and is unable to eliminate free radicals and pro-inflammatory factors in a timely manner. The level of inflammation will increase accordingly, and the skin will tend to be more fragile and sensitive. Staying up late will make us more prone to acne breakouts, and changing seasons will make us more prone to stinging. When the body is in a state of chronic inflammation for a long time, low-level chronic inflammation will gradually accumulate. Inflammation will cause a series of damage reactions in the body, such as activating matrix metalloproteinases (MMPs). These enzymes will cause the degradation of collagen and elastin in the dermis, which will lead to accelerated sagging and collapse of the skin and the appearance of wrinkles, which will further aggravate aging and form a vicious cycle. Summary of the invention

[0005] The purpose of the present application is to overcome the deficiencies of the above-mentioned prior art and provide a composition for improving skin inflammatory aging and its application. On the one hand, the composition of the present application can promote the synthesis of type I collagen, the most important component of ECM (extracellular matrix) in the dermis, and can improve skin wrinkles; on the other hand, it can remove DPPH free radicals, inhibit the release of inflammatory factors such as IL-6 and TNF-α, promote the improvement and recovery of skin inflammation symptoms, and reduce the degradation of dermal collagen and elastin caused by skin inflammation, thereby achieving the dual effects of anti-inflammatory and anti-aging.

[0006] To achieve the above purpose, the technical solution adopted by this application is:

[0007] In a first aspect, the present application provides a composition for improving skin inflammatory aging, the composition comprising the following components:

[0008] Silybin phospholipid complex, phytol, and silanediol salicylate;

[0009] The silybin phospholipid complex comprises silymarin and lecithin.

[0010] Preferably, the mass ratio of silymarin to lecithin is 35:65.

[0011] Silybin in the silybin phospholipid complex is the compound with the strongest antioxidant activity and the richest biological content extracted from milk thistle, and is the best natural substitute for A-type alcohol. It can promote cell growth and proliferation, promote the synthesis of the most important components of ECM (extracellular matrix) in the dermis (type I collagen, type III collagen and hyaluronic acid), and collagen is the key to the formation of collagen fibrils; in addition, it inhibits the expression of MMP and inhibits the degradation of collagen and elastin in the dermis; it achieves the dual effect of promoting collagen synthesis and inhibiting collagen degradation. At the same time, combined with phospholipid complex technology, the skin affinity of active ingredients is improved and the bioavailability is improved.

[0012] Phytol is a component of chlorophyll, also known as plant VA alcohol, a non-cyclic diterpene alcohol, and a precursor of vitamin E and vitamin K1. Studies have shown that diterpenes have anti-inflammatory and redox protective pharmacological activities. It can activate retinoic acid receptors (RAR), vitamin A receptors (RXR) and peroxisome proliferator-activated receptors (PPAR), resist DPPH free radicals, promote the synthesis of type I collagen and hyaluronic acid, reduce the release of inflammatory factors such as IL-1αIL-6 and TNF-α, and has anti-inflammatory and antioxidant properties. It is safer and milder than vitamin A derivatives on the market. It is an anti-aging and soothing A-type alcohol.

[0013] Silanediol salicylate is a derivative of salicylic acid. Silanediol salicylate can stimulate the growth of collagen and elastin fibers in the skin and reconstruct skin stability. At the same time, it can improve the skin's immune barrier, eliminate free radicals, promote the formation of endogenous hyaluronic acid, and effectively prevent the production of IL-1α, IL-6, TNF-α and other inflammatory cytokines, fight inflammation and prevent spread, and improve skin sensitivity.

[0014] In the technical solution of the present application, the inventors found that compounding the three components of silybin phospholipid complex, phytol, and silanediol salicylate has a synergistic anti-inflammatory, anti-aging and synergistic effect.

[0015] On the one hand, silybin phospholipid complex and phytol, both of which are plant A-type alcohol components, have the dual ability to synergistically scavenge DPPH free radicals and promote the synthesis of type I collagen, adding antioxidant and anti-aging effects.

[0016] On the other hand, silybin phospholipid complex and silanediol salicylate synergistically promote cell growth and proliferation, promote the synthesis of type I collagen, the most important component of ECM (extracellular matrix) in the dermis, improve skin wrinkles, and synergistically fight against aging and wrinkles;

[0017] On the other hand, phytol and silanediol salicylate synergistically inhibit the release of proinflammatory factors such as IL-1α, IL-6, TNF-α, promote the improvement of skin inflammation symptoms and the recovery of the immune barrier, reconstruct skin stability, and enable the skin to break out of the vicious cycle of aging-inflammation-inflammatory aging.

[0018] The absence of any one or any two of these three components will significantly reduce the antioxidant, anti-inflammatory and anti-wrinkle effects of the composition.

[0019] In addition, the inventors of the present application have found that after replacing the silybin phospholipid complex with silymarin, the antioxidant and collagen synthesis abilities of the composition are significantly reduced. This is because silymarin itself has poor solubility and poor affinity with the skin, and it is difficult to penetrate into the skin to exert its effects. The silybin phospholipid complex selected in the present application can improve the skin affinity and permeability of the active ingredient.

[0020] As a preferred embodiment of the composition for improving skin inflammatory aging described in the present application, the composition comprises the following components in parts by weight:

[0021] 0.1-1 parts of silybin phospholipid complex, 0.1-1 parts of phytol and 0.4-4 parts of silanediol salicylate.

[0022] As a preferred embodiment of the composition for improving skin inflammatory aging described in the present application, the composition comprises the following components in parts by weight:

[0023] 0.3-0.8 parts of silybin phospholipid complex, 0.3-0.8 parts of phytol and 1.2-3 parts of silanediol salicylate.

[0024] In the present application, when silybin phospholipid complex, phytol and silanediol salicylate are used in the above weight ranges, the composition has better anti-inflammatory and anti-aging effects.

[0025] As a preferred embodiment of the composition for improving skin inflammatory aging described in the present application, the composition comprises the following components in parts by weight:

[0026] 0.4-0.6 parts of silybin phospholipid complex, 0.4-0.6 parts of phytol and 1.8-2.2 parts of silanediol salicylate.

[0027] As a preferred embodiment of the composition for improving skin inflammatory aging described in the present application, the composition comprises the following components in parts by weight:

[0028] 0.5 parts of silybin phospholipid complex, 0.5 parts of phytol and 2 parts of silanediol salicylate.

[0029] When the weight proportion of silybin phospholipid complex is 0.5 parts, the weight proportion of phytol is 0.5 parts and the weight proportion of silanediol salicylate is 2 parts, the combination has the best anti-inflammatory and anti-wrinkle effects.

[0030] In a second aspect, the present application provides the use of the above composition for improving skin inflammatory aging in the preparation of cosmetics.

[0031] As a preferred embodiment of the application described in the present application, the cosmetics include at least one of an aqueous solution, an essence, a skin care lotion, a face cream, an eye cream, and a face mask.

[0032] The dosage forms of the cosmetics mentioned in this application are not limited to those listed above, and all conventional dosage forms of cosmetics in the field are within the protection scope of this application.

[0033] In a third aspect, the present application provides an essence, wherein the essence comprises the following components:

[0034] 0.6-6% of the composition for improving skin inflammatory aging, 3-5% of a moisturizer, 0.03-0.05% of a chelating agent, 0.5-0.8% of a thickener, and 0.3-0.6% of a preservative, and the balance is water;

[0035] The moisturizing agent includes at least one of glycerin, polyglycerin, diglycerin, butylene glycol, 1,3-propylene glycol, methyl propanediol, dipropylene glycol, 1,2-hexanediol, betaine, trehalose, xylitol and sodium hyaluronate;

[0036] The chelating agent includes disodium EDTA and / or tetrasodium EDTA;

[0037] The thickener comprises at least one of carbomer, xanthan gum, polyacrylate cross-polymer-6, acrylic acid (ester) / C10-30 alkyl acrylate cross-polymer, acrylic acid (ester) copolymer sodium, and lecithin;

[0038] The preservative includes at least one of methylparaben, sodium benzoate, chlorphenesin, phenoxyethanol, potassium sorbate, p-hydroxyacetophenone, 1,2-hexanediol and caprylhydroxamic acid.

[0039] Preferably, the moisturizer is composed of glycerol and 1,3-propylene glycol; the chelating agent is disodium EDTA; the thickener is sodium acrylic acid (ester) copolymer, lecithin and xanthan gum; and the preservative is p-hydroxyacetophenone.

[0040] The present application adopts the above-mentioned moisturizer, chelating agent, thickener and preservative as auxiliary agents, and uses them in combination with a composition consisting of silybin phospholipid complex, phytol and silanediol salicylate, so that the essence can have better anti-inflammatory and anti-wrinkle effects.

[0041] In a fourth aspect, the present application provides a method for preparing the above-mentioned essence, the method for preparing the essence comprising the following steps:

[0042] 1) Mix water, moisturizer, chelating agent and thickener, stir and heat to 80-85° C., stir evenly to obtain material A;

[0043] 2) mixing the silybin phospholipid complex and the polyol uniformly, adding xanthan gum, stirring and mixing, adding water, standing and hydrating to obtain a mixture, then heating the mixture to 45-60° C., adding phytol and silanediol salicylate, stirring, homogenizing and not stratifying, and obtaining material B;

[0044] 3) Add material B to material A, stir and heat to 80-85° C., homogenize, then cool to 45-50° C., add preservatives, stir evenly, and obtain the essence.

[0045] Since silybin phospholipid complex can only be dispersed in water and alcohol, while phytol is soluble in oil and silanediol salicylate is soluble in water, the three substances are not compatible. Therefore, silybin phospholipid complex, phytol and silanediol salicylate are pre-treated through the above-mentioned specific process to make a combination of the three, which can be better dispersed evenly, more easily penetrate into the skin, and improve bioavailability, thereby exerting a synergistic anti-inflammatory and anti-aging effect.

[0046] The inventors of the present application have found that after the silybin phospholipid complex, phytol, and silanediol salicylate of the present application are subjected to the above-mentioned pretreatment process, the composition has better dispersibility and permeability in the system, and therefore has better anti-inflammatory and anti-wrinkle effects.

[0047] Compared with the prior art, this application has the following beneficial effects:

[0048] The present application uses the main functional ingredients Silybin phospholipid complex, phytol, and silanediol salicylate for compounding and combining, and through the optimization of the component ratio, the cosmetics can have more excellent antioxidant, anti-inflammatory and anti-aging effects. Moreover, these three components complement each other in efficacy and have a synergistic effect. The selected Silybin phospholipid complex, compared with the single silymarin, improves its dispersibility, improves the skin affinity and permeability of the active ingredient, and then enhances the antioxidant and collagen synthesis effects of the active ingredient. And the present application uses a specific pretreatment process for the main functional ingredients Silybin phospholipid complex, phytol, and silanediol salicylate to further improve the compatibility and stability between the components, ensure that the active components are uniformly stable in the formula system, and are more conducive to the synergistic effect of the three components. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] Figure 1 The results of the effect tests of the essences prepared in Examples 1 to 5 are shown;

[0050] Figure 2 The effect test results of Example 5 and Comparative Examples 1 to 7 are shown;

[0051] Figure 3 The effect test results of Example 5 and Comparative Examples 8 to 9 are shown in FIG.

[0052] Figure 4 The effect test results of Example 5 and Comparative Examples 10 to 13 are shown;

[0053] Figure 5 It is a graph showing the effect test results of Example 5 and Comparative Example 14. DETAILED DESCRIPTION

[0054] In order to better illustrate the purpose, technical solutions and advantages of the present application, the present application will be further described below in conjunction with the accompanying drawings and specific embodiments.

[0055] In the following examples and comparative examples, the experimental methods used are conventional methods unless otherwise specified, and the materials, reagents, etc. used are all commercially available unless otherwise specified.

[0056] In the examples and comparative examples of the present application, the trade name of the silybin phospholipid complex (including silymarin and lecithin in a mass ratio of 35:65) is Siliphos, and the manufacturer is Givandan. The trade name of phytol is Phytol, and the manufacturer is BASF. The trade name of silanediol salicylate is DSB C SP2, and the manufacturer is EXSYMOL SAM.

[0057] Examples 1 to 15: Essence for improving inflammatory aging of the skin

[0058] This embodiment provides a formula of an essence for improving inflammatory aging of the skin. The specific formula (percentage content) is shown in Table 1.

[0059] The preparation method of the essence for improving skin inflammatory aging of this embodiment comprises the following steps:

[0060] 1) Add water, humectant (glycerol, 1,3-propylene glycol), chelating agent (disodium EDTA) and thickener (sodium acrylic acid (ester) copolymer, lecithin and xanthan gum) into a main pot, mix, stir and heat to 85° C., stir for 30 minutes until completely uniform, and obtain material A;

[0061] 2) mixing the silybin phospholipid complex and the polyol uniformly, adding xanthan gum, stirring and mixing, adding water, standing and hydrating for 2 hours to obtain a mixture, then heating the mixture to 60° C., adding phytol and silanediol salicylate, stirring, and homogenizing at 3000 rpm for 10 minutes until the system is completely uniform and not stratified, to prepare a three-phase complex, and obtain material B (i.e., a composition for improving skin inflammatory aging);

[0062] 3) Add material B to material A, stir and heat to 85° C., homogenize at 3000 rpm for 10 minutes until completely uniform, then cool to 45° C., add preservative (p-hydroxyacetophenone), stir evenly, and obtain the essence.

[0063] Table 1

[0064]

[0065]

[0066] Comparative Examples 1 to 13

[0067] Compared with Example 5, Comparative Examples 1 to 13 differ in that the formulations are different, as shown in Table 2, and the rest of the preparation methods are the same as those of Example 5.

[0068] Table 2

[0069]

[0070]

[0071] Comparative Example 14

[0072] Comparative Example 14 adopts the common process (i.e., silybin phospholipid complex, phytol, and silanediol salicylate are not pretreated) as follows:

[0073] S1. Add water, humectant (glycerol, 1,3-propylene glycol), chelating agent (disodium EDTA) and thickener (sodium acrylic acid (ester) copolymer, lecithin and xanthan gum) into the main pot, stir and heat to 80-85° C., stir for 30 minutes until completely uniform, and obtain material A;

[0074] S2. Add silybin phospholipid complex, phytol and silanediol salicylate into the main pot in sequence, and homogenize at 3000 rpm for 10-15 minutes until the system is completely uniform.

[0075] S3, cooling to 45-50°C, adding preservative (p-hydroxyacetophenone), stirring until uniform, and obtaining the essence.

[0076] Effect test example

[0077] The essences prepared in Examples 1 to 15 and Comparative Examples 1 to 14 were subjected to antioxidant, anti-inflammatory and anti-wrinkle tests.

[0078] 1. Antioxidant test:

[0079] In vitro test: The DPPH free radical scavenging experiment was used to evaluate the in vitro antioxidant efficacy of the samples.

[0080] The calculation formula of DPPH free radical scavenging rate is: scavenging rate (%) = [1-(Ai-Aj)Ac]×100.

[0081] Free radical scavenging experiment: Take 2mL of 0.2mM DPPH as the working solution as an example, where Ac is the absorbance value of 2mL 95% ethanol plus 2mL DPPH working solution; Ai is 2mL of the sample to be tested with different concentrations added to 2mL DPPH, mixed and reacted at room temperature in the dark for 30 minutes, and the absorbance value was measured at a wavelength of 517nm; Aj is the control, and the value is the absorbance value measured by adding 2mL of the solution of the test sample with the corresponding concentration to 2mL of anhydrous ethanol. In the experiment, the absorbances were measured respectively, and the scavenging rate of the test sample on DPPH free radicals can be calculated.

[0082] 2. Anti-inflammatory test:

[0083] The anti-inflammatory effect of the samples was evaluated by testing the content of intracellular tumor necrosis factor (TNF-α) and interleukin-6 (IL-6).

[0084] 1) Reagent preparation

[0085] Experimental plan: HaCaT cells in logarithmic growth phase were taken and cultured at 3×10 5 The cells were inoculated in 6-well plates at a density of 100 / well. They were divided into negative control, model control and experimental groups, with three parallels in each group. The cells were cultured with DMEM complete medium until 80% confluence, the medium was removed, and the cells were carefully rinsed with PBS twice. 1 mL of PBS was added, and the cells in the model group and the experimental group were exposed to 10 mJ / cm 2 After irradiation, PBS was removed and the experimental group was replaced with DMEM complete medium containing samples.

[0086] The blank group and the model group were treated with DMEM complete medium without samples as controls and cultured for 24 hours. The cell supernatant was collected.

[0087] The contents of TNF-α and IL-6 in the cell supernatant were detected using ELISA kits according to the instructions.

[0088] 2) Experimental methods:

[0089] 30 minutes before the experiment, take out the test kit and return to room temperature. Before adding the standard / sample, wash the plate 3 times and spin dry; add 100μl of the standard and the test sample to the reaction well, seal the plate and incubate in a 37℃ incubator for 90 minutes; add 100μl of the biotinylated antibody working solution to the reaction well, seal the plate and incubate in a 37℃ incubator for 60 minutes; add 50μl of the stop solution and immediately measure the OD value at a wavelength of 450nm using an enzyme reader (within 5 minutes); add 100μl of the color substrate to the reaction well, seal the plate and color develop at 37℃ in the dark for 15 minutes; add 100μl of the enzyme conjugate working solution to the reaction well, seal the plate and incubate in a 37℃ incubator for 30 minutes; measure the OD value at a wavelength of 450nm using an enzyme reader. Select dual-wavelength detection, with a reference wavelength of 630nm; if dual-wavelength detection is not possible, subtract the OD value at 630nm from the OD value at 450nm. Calculate the average OD value of the standard and sample: the OD value of each standard and sample should be subtracted from the OD value of the zero well. Use the standard concentration as the horizontal axis and the absorbance OD value as the vertical axis to draw a standard curve using software. The TNF-α and IL-6 content in the sample can be converted to the corresponding concentration from the standard curve through the corresponding OD value.

[0090] 3. Anti-wrinkle test:

[0091] Zebrafish type I collagen gene expression promotion test, collagen is the most abundant protein in the human extracellular matrix, among which type I collagen is the most abundant protein in the skin. The distribution of type I collagen in zebrafish is the same as that in humans, and it shows a high degree of conservation with humans. The expression of zebrafish type I collagen genes (col1a1a, col1a1b and col1a2) was tested, and the relative expression of zebrafish type I collagen genes in the treatment group and the blank control group was compared. The type I collagen gene expression promotion rate was calculated to evaluate the anti-wrinkle and firming effects of the sample. 36 6-day-old zebrafish were divided into 3 groups and exposed to the sample solution. A blank control group was set up at the same time. After 24 hours of exposure, RNA extraction, cDNA synthesis, and real-time PCR amplification were performed on the zebrafish. β-actin was used as the housekeeping gene and Ct was used as the amplification result. The relative expression of col1a1a, col1a1b and col1a2 was calculated and statistically analyzed.

[0092] The results are shown in Table 2.

[0093] Table 2

[0094]

[0095]

[0096] The results are shown in Table 2 and Figure 1-5As shown, the essence prepared in the embodiment of the present application is compounded and used with silybin phospholipid complex, phytol, and silanediol salicylate. By optimizing the proportion of the components, the cosmetics can have more excellent antioxidant, anti-inflammatory, and anti-aging effects. Moreover, these three components complement each other in terms of efficacy and have synergistic anti-inflammatory and anti-aging effects.

[0097] Compared with Example 5, Comparative Examples 1 to 7 do not contain silybin phospholipid complex, phytol and silanediol salicylate, or only contain one or two of silybin phospholipid complex, phytol and silanediol salicylate. The anti-inflammatory and anti-aging effects of the prepared essences are not as good as those of Example 5 of the present application.

[0098] Compared with Example 5, after the silybin phospholipid complex was replaced with silymarin in Comparative Examples 8-9, the antioxidant and collagen synthesis abilities of the composition were significantly deteriorated. This is because silymarin itself has poor solubility and poor skin affinity, and it is difficult to penetrate into the skin to exert its effect. Compared with single silymarin, the silybin phospholipid complex selected in this application improves its dispersibility, enhances the skin affinity and permeability of the active ingredient, and thus enhances the antioxidant and collagen synthesis promoting effects of the active ingredient. The silybin phospholipid complex selected in this application can improve the skin affinity and permeability of the active ingredient.

[0099] Compared with Example 5, the weight proportion of silybin phospholipid complex in Comparative Examples 10 to 13 is not within the range of 0.1 to 1 part, the weight proportion of phytol is not within the range of 0.1 to 1 part, and the weight proportion of silanediol salicylate is not within the range of 0.4 to 4 parts. The anti-inflammatory and anti-aging effects of the essences prepared therefrom are not as good as those of Example 5.

[0100] Compared with Example 5, in Comparative Example 14, silybin phospholipid complex, phytol, and silanediol salicylate were not pretreated. Since silybin phospholipid complex can only be dispersed in water and alcohol, while phytol is soluble in oil and silanediol salicylate is soluble in water, the three substances are not compatible, and the anti-inflammatory and anti-aging effects are poor. Therefore, silybin phospholipid complex, phytol, and silanediol salicylate are pretreated by a specific process to prepare a complex of the three, which can be better dispersed evenly, more easily penetrate into the skin, and improve bioavailability, thereby exerting a synergistic anti-inflammatory and anti-aging effect.

[0101] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present application rather than to limit the scope of protection of the present application. Although the present application has been described in detail with reference to the preferred embodiments, ordinary technicians in this field should understand that the technical solution of the present application can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present application.

Claims

1. A composition for improving skin inflammatory aging, characterized in that: The composition comprises the following components in parts by weight: 0.1-1 part of silybin phospholipid complex, 0.1-1 part of phytol and 0.4-4 parts of silanediol salicylate; The silybin phospholipid complex comprises silymarin and lecithin; The preparation method of the composition for improving skin inflammatory aging comprises the following steps: The silybin phospholipid complex and the polyol are uniformly mixed, xanthan gum is added, stirred and mixed, water is added, and the mixture is allowed to stand for hydration to obtain a mixture, and then the mixture is heated to 45-60° C., phytol and silanediol salicylate are added and stirred, and the mixture is homogenized evenly without stratification to obtain a composition for improving skin inflammatory aging.

2. The composition for improving skin inflammatory aging according to claim 1, characterized in that: The composition comprises the following components in parts by weight: 0.3-0.8 parts of silybin phospholipid complex, 0.3-0.8 parts of phytol and 1.2-3 parts of silanediol salicylate.

3. The composition for improving skin inflammatory aging according to claim 2, characterized in that: The composition comprises the following components in parts by weight: 0.4-0.6 parts of silybin phospholipid complex, 0.4-0.6 parts of phytol and 1.8-2.2 parts of silanediol salicylate.

4. The composition for improving skin inflammatory aging according to claim 3, characterized in that: The composition comprises the following components in parts by weight: 0.5 parts of silybin phospholipid complex, 0.5 parts of phytol and 2 parts of silanediol salicylate.

5. Use of the composition for improving skin inflammatory aging according to any one of claims 1 to 4 in the preparation of cosmetics.

6. The use according to claim 5, characterized in that The cosmetics include at least one of an aqueous solution, an essence, a skin care lotion, a face cream, an eye cream, and a face mask.

7. An essence, characterized in that: The essence comprises the following components in percentage by weight: 0.6-6% of the composition for improving skin inflammatory aging as claimed in any one of claims 1 to 4, 3-5% of a moisturizer, 0.03-0.05% of a chelating agent, 0.5-0.8% of a thickener and 0.3-0.6% of a preservative, and the balance being water.

8. The essence according to claim 7, characterized in that The moisturizing agent includes at least one of glycerin, polyglycerin, diglycerin, butylene glycol, 1,3-propylene glycol, methyl propanediol, dipropylene glycol, 1,2-hexanediol, betaine, trehalose, xylitol and sodium hyaluronate; The chelating agent includes disodium EDTA and / or tetrasodium EDTA; The thickener comprises at least one of carbomer, xanthan gum, polyacrylate cross-polymer-6, acrylic acid (ester) / C10-30 alkyl acrylate cross-polymer, acrylic acid (ester) copolymer sodium and lecithin; The preservative includes at least one of methylparaben, sodium benzoate, chlorphenesin, phenoxyethanol, potassium sorbate, p-hydroxyacetophenone, 1,2-hexanediol and caprylhydroxamic acid.

9. The method for preparing the essence according to claim 8, characterized in that the method for preparing the essence comprises the following steps: 1) Mix water, moisturizer, chelating agent and thickener, stir and heat to 80-85° C., stir evenly to obtain material A; 2) mixing the silybin phospholipid complex and the polyol uniformly, adding xanthan gum, stirring and mixing, adding water, standing and hydrating to obtain a mixture, then heating the mixture to 45-60° C., adding phytol and silanediol salicylate, stirring, homogenizing and not stratifying, and obtaining material B; 3) Add material B to material A, stir and heat to 80-85° C., homogenize, then cool to 45-50° C., add preservatives, stir evenly, and obtain the essence.

Images